Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

BACKGROUND: Chronic active antibody-mediated rejection (c-aABMR) is an important cause of allograft failure and graft loss in long-term kidney transplants. METHODS: To determine the efficacy and safety of combined therapy with rituximab, plasma exchange (PE) and intravenous immunoglobulins (IVIG), a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Nephrol
Auteurs principaux: Piñeiro, Gastón J, De Sousa-Amorim, Erika, Solé, Manel, Ríos, José, Lozano, Miguel, Cofán, Frederic, Ventura-Aguiar, Pedro, Cucchiari, David, Revuelta, Ignacio, Cid, Joan, Palou, Eduard, Campistol, Josep M, Oppenheimer, Federico, Rovira, Jordi, Diekmann, Fritz
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182805/
https://ncbi.nlm.nih.gov/pubmed/30309322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-018-1057-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires